Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner


...see all

Biologics market will reach $178.4bn in 2017, predicts new visiongain report

A new report by London-based business information company visiongain predicts the world biological drugs market will reach $178.4bn in 2017. That forecast and others appear in World Biological Drugs Market 2013-2023, published in May 2013.

In 2012, biologics represented 15% of the global pharmaceutical market, including seven of the top 10 products. Led by Humira and Remicade, monoclonal antibodies (mAbs) made up 41% of the 2012 market, fusion proteins 8%, and cellular and regenerative medicines 1%. The remainder of biologics revenues came from a range of protein therapeutics, with insulin and other recombinant hormones the most significant agents.

MAbs have the strongest R&D pipeline in the biologics market, the report indicates, with a range of next-generation technologies pushing mAb therapeutics into newer areas, including solid tumours, cardiovascular and neurological disorders. Diabetes represents a major growth opportunity for biologics, with new fusion proteins set to join Novo Nordisk’s Tresiba and other novel insulins on the market in the near future. Competition to develop the next wave of blockbusters in these areas and in the recombinant clotting proteins segment will offset revenue loss from waning erythropoietin and G-CSF products.

Dr James Evans, a pharmaceutical industry analyst in visiongain, said: “Biologics were one, two and three in the top ten drugs of 2012. People talk about the biotech revolution, but biotech is now one of the dominant, established powers in the pharmaceutical industry. All the main biotechs have either been acquired by Big Pharma or become major players in their own right.

“The next big shift will come when biosimilars start to reach the market. The approval of LG Life Sciences’ biosimilar infliximab in South Korea is a sign of what’s to come. Once the EU’s new regulatory pathway for biosimilars has been established, we can expect the major markets to be inundated with biosimilars and biobetters. The entry barriers for bio-manufacturing and bio-processing have been greatly reduced, and even the suite of technologies that built the mAb market, from phage display to transgenic mice, are now off-patent and accessible to any company that’s interested. And biologics are going to become so prevalent that every major company will be interested in having a stake in that expanding market.

“In terms of the multiple-blockbuster biologics, there hasn’t been a new one since Lucentis was approved in 2006. But the market continues to expand and broaden with a stream of new additions, and that will continue. There are also plenty of new technology platforms. From the approval of the Glybera gene therapy to the ADCs and other new antibody formats, to the new wave of stem cell therapeutics, there’s still a lot of exciting innovation in this market.”

Visiongain’s report shows revenue forecasts to 2023 at world market, submarket, product and national level. It forecasts these world-level submarkets:

  • Protein therapeutics – with sub forecasts for insulins, other recombinant hormones, plasma and recombinant coagulating factors, interferons, and other agents
  • Monoclonal antibodies (mAbs) – with sub forecasts for autoimmune, anticancer, and other agents
  • Fusion proteins
  • Cellular and regenerative medicines – with sub forecasts for tissue-engineered products, cellular therapies, and gene therapy.

The investigation predicts revenues of leading drugs in the biologics market to 2023, including Lantus, Epogen, NovoRapid, Humira, Remicade, Rituxan, Herceptin and Avastin. Research, data and analyses cover activities of Roche, Amgen, Novo Nordisk, AbbVie, Johnson & Johnson and other biopharmaceutical companies.

That new study also discusses R&D and commercial activity, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).

World Biological Drugs Market 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Visiongain report World Biological Drugs Market 2013-2023 please visit  


For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.